Keywords
Diabetes Mellitus ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

524 Search results.

Eligibility NCT00322621 Diabetic Neuropathies - Eligibility

- 8/11/14 - 1 form, 2 itemgroups, 9 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00322621

LASER ADMINISTRATION FELLOW EYE (UNSCHEDULED) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/28/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Patient administration, LASER ADMINISTRATION STUDY EYE
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/11/17 - 1 form, 3 itemgroups, 12 items, 1 language
Itemgroups: Patient administration, CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12), Procedure
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

SUBJECT ELIGIBILITY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 6/8/17 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Patient administration, SUBJECT ELIGIBILITY, Eligibility Criteria Not Met
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Diabetes-related baseline data

- 10/30/20 - 1 form, 12 itemgroups, 26 items, 1 language
Itemgroups: Diabetes type, Duration of diabetes, Hemoglobin A1c (HbA1c ) in blood, C-peptide in blood, Glucose in blood, C-peptide-to-Glucose Ratio (CGR) in blood, Insulin level in blood, Cortisol level in blood, Insulin treatment before SARS-CoV-2 detection, Change of insulin scheme at the time of SARS-CoV-2 detection (+/- 48 h), Oral antidiabetic treatment before SARS-CoV-2 detection, Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 15:31 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Diabetes-related baseline data. If a text field can't be filled out, note 'ND'.

Measurement Instrument Database for the Social Science (MIDSS) - Appraisal of Diabetes Scale (ADS)

- 9/13/20 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: DCAI-R (7/88)
Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Appraisal of Diabetes Scale (ADS). Measurement Instrument Database for the Social Science. Retrieved 13.09.20, from www.midss.ie Key references: Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Reliability and validity of the appraisal of diabetes scale. Journal of Behavioral Medicine, 14, 43-51. Garratt, A.M., L. Schmidt, and R. Fitzpatrick (2002) Patient-assessed health outcome measures for diabetes: a structured review. Diabetic Med., 19, 1-11. Trief, P.M., W. Grant, K. Elbert, and R.S. Weinstock (1998) Family environment, glycemic control, and the psychosocial adaptation of adults with diabetes. Diabetes Care 21, 241-245. Trief, P.M., C. Aquilino, K. Paradies, and R.S. Weinstock (1999) Impact of the work environment on glycemic control and adaptation to diabetes. Diabetes Care 22, 569-574. Primary use / Purpose: The Appraisal of Diabetes Scale (ADS) is a 7-item self-report scale assessing the individual's appraisal of his or her diabetes. Respondents rate each statement on a 5 point Likert scale. The scale's author state that the ADS can be incisive as a relatively quick (5 minute) screening tool to examine a patient’s adjustment to diabetes or risk for noncompliance with a care regimen. The test is easily administered (written or oral form) and is simple to score and interpret. The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better. Background: The Appraisal of Diabetes Scale (ADS) was developed and tested with 200 male subjects, two thirds of whom were taking insulin treatment with an mean age of 58 years. All subjects provided blood for routine monitoring of HbA1c, half the subjects completed the ADS as well as five other self-report measures, and the other half completed the ADS on three time points over the course of one week. No significant difference was observed between ADS scores for insulin-dependent and non-insulin-dependent subjects. The ADS has been used in studies parsing the effects of family environment (Trief et al. 1998) and work environment (Trief et al. 1999) on glycemic control and psychosocial adaptation in adults with diabetes. Psychometrics: The psychometric properties of the ADS are examined in Carey et al. (1991). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.274 Scoring the ADS is easy: 1. Reverse score items # 2 and 6. ADS2R = 5 - ADS2 ADS6R = 5 - ADS6 2. Then sum all items, using the reversed scored items 2 and 6. Total score = ADS1 + ADSR2 + ADS3 + ADS4 + ADS5 + ADSR6 + ADS7 There is no manual. Interpretation is straightforward: The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better.

Eligibility Loss of Control of Diabetes NCT01889706

- 7/5/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Metformin Therapy in Type 1 Diabetes Mellitus.; ODM derived from: https://clinicaltrials.gov/show/NCT01889706

Eligibility Islet Transplantation in Diabetes Mellitus Type 1, NCT01817959

- 4/28/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01817959

Eligibility Diabetes NCT02351323

- 11/19/19 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Novel Type 2 Diabetes Mellitus Preventive Therapies; ODM derived from: https://clinicaltrials.gov/show/NCT02351323

Eligibility Diabetes NCT02219269

- 11/19/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Complex Contraception Registry; ODM derived from: https://clinicaltrials.gov/show/NCT02219269

Eligibility Diabetes NCT02161588

- 11/18/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT02161588

Eligibility Diabetes NCT02146079

- 11/18/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT02146079